ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of Lytenava (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, has announced…
The FDA approved the first formulation of bevacizumab specifically for the treatment of neovascular (wet) age-related macular degeneration (nAMD), Outlook Therapeutics announced on Friday. The approval of bevacizumab-vikg (Lytenava) follows…
MONTREAL — Complement inhibitors to treat geographic atrophy (GA) were associated with thickening of the retinal nerve fiber layer (RNFL), which could be helpful or pathologic, according to a study…
MONTREAL — Geographic atrophy (GA) had a similar response to the complement inhibitor pegcetacoplan (Syfovre) whether concurrent with neovascular age-related macular degeneration (nAMD) or alone, data from a retina clinical…
MONTREAL — An investigational bispecific antibody for retinal disease achieved faster and numerically greater short-term improvements in visual acuity and retinal anatomy versus faricimab (Vabysmo), a randomized, proof-of-concept trial showed.…
Loss of copayment assistance for drugs to treat neovascular age-related macular degeneration forces patients onto alternative, potentially less effective treatment strategies. Patients who switched to bevacizumab required significantly more frequent…
Compare health Insurance & supplemental plans from trusted insurance providers. Get personalized quotes in minutes and speak with a licensed agent today.
Enter your ZIP code to see plans available in your area.
